The burden associated with the rising prevalence of myopia and high myopia, and the associated vision impairment and sight-threatening complications, has triggered the need to evaluate strategies to control the progression of myopia. We provide an overview of the literature on the use of optical (spectacles, contact lenses, and orthokeratology) and pharmaceutical approaches to slow progress of myopia. The evidence indicates that myopia progression can be slowed by varying degrees using these strategies. All approaches play a role in the management of myopia as needs and requirements of an individual vary based on age, suitability, affordability, safety of the approach, subjective needs of the individual, and rate of progression. This review also identifies and discusses the lack of long-term efficacy data and rebound on discontinuation of myopia control products.
rising prevalence of myopia and aging of the population, 11 it is expected that there will be an increased risk of future events of myopic maculopathy, retinal detachment, cataract, retinal breaks, and glaucoma.
Interplay between genetic and environmental factors has been shown to influence the onset and progression of myopia; however, environmental influences are considered to play a significant role. This is evidenced by work demonstrating modulation of eye growth by visual feedback in animal models, 12 along with human observational studies showing an association of myopia with urban societies, higher socioeconomic status, greater amount of near work, and lack of outdoor time. 13, 14 Furthermore, genetic change was slow to explain the nature of rapid increase in the prevalence of myopia observed in many East Asian and Southeast Asian countries. 2 Over the years, there have been efforts to slow the progression of myopia with optical, environmental, and pharmaceutical strategies, but in response to the rising global burden, these efforts have increased substantially in the past 2 decades, confirmed by a large number of peer-reviewed reports (Tables 1, 2 ) and meta-analyses. 15, 16 Although translation and implementation of the research findings to mainstream clinical practice is gaining traction, it lacks momentum in many countries due to lack of data on long-term treatment efficacy, rebound on discontinuation of treatment, practitioner's perception of myopia control, lack of access to myopia control products, and lack of regulatory approval.
In this review, in addition to summarizing the evidence for treatment efficacy with optical and pharmaceutical strategies for myopia control, we discuss some of the challenges in obtaining long-term data and rebound on discontinuation of treatment.
CANDIDATES FOR MYOPIA CONTROL
As certain individuals are at risk of developing high myopia, it is important to identify the at-risk group to ensure better outcomes with respect to their ocular health and vision. With an onset commonly found in school-age children between the ages of 6 and 12, myopia progresses before commonly stabilizing during adolescence; although in a few eyes, progression continues well beyond teenage years and into adulthood. 17, 18 A progression model was derived based on a meta-analysis of articles that reported annual progression of myopia in children of Asian and European ethnicity using single-vision spectacles. 19 Greater progression was observed with younger ages and those of Asian ethnicity. In addition to these individuals, those with a faster-than-average progression or a greater number of years in progression mode are at risk of becoming highly myopic and should be considered for myopia control treatment. Recent evidence indicates that the age of onset has also decreased, thus contributing to a greater number of years in progression mode and increasing the risk of becoming Cheng et al, 52 
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CL indicates contact lens; cyl, cylinder; Exec bifocal, executive bifocal; PAL, progressive addition spectacle; PA-PAL, peripheral asphericized progressive addition spectacle; Perip def mgmt, peripheral defocus management; Perip Plus, peripheral plus; +SA, positive spherical aberration. 25, 26 and reduced outdoor time 27 are thought to influence myopia progression but their role is not entirely clear. For example, some studies have not found a correlation between accommodative lag and progression, [28] [29] [30] and although increased outdoor time seems to play a role in delaying the onset of myopia, it does not seem to play a role in slowing progression in eyes that are already myopic. 31 
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STRATEGIES FOR MYOPIA CONTROL
The past couple of decades have witnessed a surge in the number of strategies utilizing optical, pharmaceutical, and environmental approaches to slow the progression of axial myopia. As a myopic eye already has an axial length that is longer than the optical focal length of the eye, an ideal myopia control strategy would prevent further axial growth to stop any concomitant increase in myopia and to reduce the risk of developing sightthreatening conditions such as glaucoma or myopic maculopathy. Modeling predicts that a myopia control strategy that can slow myopia by 30% to 40% is instituted early, this substantially reduces the risk of high myopia and associated complications. 32, 33 Although studies conducted using 1% atropine suggest that it is feasible to halt eye growth, 34 rebound of myopia observed on discontinuation of atropine 35, 36 and with orthokeratology 37, 38 indicate that the mechanisms underlying eye growth are not fully understood. Given the above, once myopia control treatment is instituted, it may be desirable to continue with the treatment well past the period of progression (ie, through adolescence and into early adulthood).
OPTICAL APPROACHES FOR MYOPIA CONTROL
Progression with myopia control treatments was commonly benchmarked against progression observed with single-vision spectacles or single-vision soft contact lenses. Although no difference in progression was observed between single-vision spectacles and contact lenses, 39 there are limited data and it is not clear if factors that influence peripheral retinal defocus, such as the power profile of the contact lens 40 or pantoscopic tilt with spectacle lenses, 41 might influence progression. In experimental models, relative hyperopic defocus at the retina was observed to drive axial elongation, whereas relative myopic defocus slowed or inhibited eye growth. 12 Inaccurate or insufficient accommodative response for near tasks resulted in retinal hyperopic defocus at the central retina and was thought to trigger axial elongation. Indeed, accommodative lag was found in myopic eyes. 25 More recent observations from animal models indicated that the peripheral retina can dominate and drive emmetropization 42 and also found that hyperopic defocus at the peripheral retina can drive axial elongation. Furthermore, myopic eyes were found to suffer from relative peripheral hyperopia 21, 43 ; however, it is not fully evident that there is an association between relative peripheral hyperopia and onset and progression of myopia.
The above spectacles and contact lenses for myopia control were designed to reduce the hyperopic defocus and induce myopic defocus at the central retina during near work or at the for 5 hours or more per day and improved from 25% to 46% less progression. 61 In orthokeratology, the optical zone of the rigid contact lens incorporates a central zone that is flatter than the flattest corneal curvature and a steeper midperipheral reverse curve. When worn overnight, the lens induces flattening of the central cornea and steepening of the midperiphery, resulting in an image profile that corrects for the distance refractive error at the fovea of the retina with relative myopic defocus at the periphery. 63 The treatment efficacy with these lenses ranged from 30% to 56%. [67] [68] [69] [70] [71] With all the optical approaches, the overall efficacy represents the mean reduction seen across a number of eyes in comparison with a control, and therefore, it is possible that some eyes derive greater benefit compared with other eyes.
PHARMACEUTICAL STRATEGIES FOR MYOPIA CONTROL
Candidate compounds assessed for myopia control in human trials include atropine, pirenzepine, tropicamide, 7-methylxanthine, and certain intraocular pressure-lowering agents such as timolol. Of these, selective muscarinic receptor antagonists such as pirenzepine and mydriatic agents such as tropicamide showed some early promising data, 72, 73 but for reasons unknown, there were no further clinical reports and no approved products for use. Rhythmic variations along with raised intraocular pressure are considered to exert force on the sclera triggering excessive growth, 74, 75 although a causal relation is yet to be proven. 76 However, in a single trial, 0.25% timolol applied twice daily did not have any effect in controlling myopia progression. 77 
Atropine
Early use of atropine was based on its (presumed) action on accommodative mechanism, 78, 79 as prolonged accommodation was considered to result in force on the choroid and sclera. However, studies in chicks showed that atropine acted through nicotinic rather than muscarinic receptors in the ciliary muscle. 80 Later work explored the action of atropine on retinal neurotransmitters, choroid, retinal pigment epithelium, and sclera; however, it remains unclear as to whether atropine exerts its action through antimuscarinic activity via the M1-M5 receptors, via direct action on tissues, or via action on other receptors. 81, 82 Atropine 1% was used in early studies. 83, 84 Although effective in slowing eye growth, there were significant adverse effects related to atropine-induced cycloplegia such as photophobia and blurred near vision that required management with bifocal and photochromic spectacles. In addition, there were concerns on whether long-term use of atropine causes photic damage or toxicity to the retina from accumulation of drug; however, the retinal response and function were unaltered. 85, 86 Nevertheless, given the significant adverse effects associated with use of higher concentrations, lower concentrations of atropine of up to 0.01% were trialled. Figure 1 details the efficacy data with respect to change in spherical equivalent compared with controls from all trials that considered atropine in any concentration and found even lower concentrations to be significantly effective in slowing myopia. 84, [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] This new understanding has led to a surge in the popularity of 0.01% atropine; but on closer examination, although there was a significant change in spherical equivalent with 0.01% atropine, there was no corresponding significant peripheral retina for all viewing distances. Commonly, such lenses feature (1) 1 or more region(s) designed to correct the myopic refractive error and restore vision and (2) 1 or more region(s) that is/are relatively more positive than the region for correcting the myopic refractive error. The relatively positive power region (plus power) is intended to reduce the hyperopic defocus and/or induce myopic defocus.
22, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] The position of this region on the lens can vary. For example, to reduce accommodative lag, the plus power is positioned such that the wearer is required to look through the plus zone while viewing near distances. Alternatively, for reduction of peripheral hyperopic defocus, the plus zone is positioned, for example, towards the periphery on the optical zone of the lens to create myopic defocus at the peripheral retina while the eye is simultaneously receiving images at the fovea to enable clear vision. In addition to spectacles and soft contact lens-based designs, rigid contact lenses used overnight for orthokeratology also had an unexpected benefit of myopia control. Originally developed for correction of myopia, orthokeratology induces flattening of the central corneal curvature and midperipheral corneal steepening and results in a retinal image profile with reduction of hyperopic defocus at the peripheral retina. 63 Spectacle-based myopia control approaches include bifocals (with and without prism), progressive addition spectacles, and lenses utilizing peripheral defocus management. 44 ,47,49-52,54,60 Using data reported from well-conducted clinical trials (mostly 1-2 years in duration), the rate of overall decrease in progression with the myopia control lens as compared with the control lens was determined for change in spherical equivalent and change in axial length (Table 1) . It is observed that although spectacle-based approaches slow myopia, the difference with respect to progression compared with standard, single-vision spectacles is small to moderate (mostly 20% or less) ( Table 1) . 16 There are some exceptions, with greater efficacy observed in a 3-year trial with bifocals (with and without prism) and in certain subgroups of individuals with esophoria or young children with parental myopia. 47 In comparison with spectacles, both contact lens and orthokeratology-based approaches show greater efficacy (Tables 1, 2) . 16 The reduced efficacy of the spectacle lenses as compared to contact lenses or orthokeratology might be related to peripheral or off-axis gazing of the eye that disrupts the signal at the retina, 64 insufficient power to reduce the hyperopic defocus, 64 or noncompliance with respect to directing gaze through specific portions of the lens for specific tasks. 65 Furthermore, the cause of myopia is not well understood enough to enable interventions that are more appropriate.
Contact lenses for myopia control are multifocal or specially designed multifocal-like lenses, having an optical zone with a central portion that corrects for the distance refractive error and 1 or more peripheral portions of relatively positive power (plus power). As described previously, the plus power was intended to reduce peripheral defocus or induce myopic defocus and commonly incorporated as rings, 56, 59, 61, 66 steps, 48 or gradually rising power. [55] [56] [57] 62 An exception is the extended-depth-of-focus (EDOF) contact lens that features a nonmonotonic power profile (ie, both relatively positive and negative zones feature in relation to the mean power and the power profile designed to degrade the image quality for points behind retina to prevent axial elongation). 58 The treatment effect with contact lenses varied from 20% to 70% for spherical equivalent and 27% to 79% for axial length. In a single study where compliance to lens wear was considered, myopia control efficacy was greater in those who wore the lenses change in axial length compared with control eyes. 87 Similarly, a more recent study also found 0.01% atropine to control spherical equivalent by a significant amount but not axial length.
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Figure 2 presents the data for change in spherical equivalent and corresponding change in axial length for data from level 1 or level 2 trials (randomized, prospective, or group-matched clinical trials) and shows a mismatch between the data for change in spherical equivalent and change in axial length, especially for lower concentrations. 34, 87, 92, 96, 97, 99 As such, use of 0.01% atropine needs further exploration. Furthermore, although lower concentrations were said to have fewer adverse effects compared with higher concentrations, 87, 101 data indicate that even at lower concentrations of up to 0.01%, significant effects were noted for pupil size and accommodation.
102,103
7-methylxanthine
A nonselective adenosine receptor antagonist, oral 7-methylxanthine has been shown in a primate model to reduce axial myopia produced by hyperopic defocus. 104 In a pilot human clinical trial involving 68 myopic children, at 12 months axial length change was less (0.35 ± 0.15 mm versus 0.38 ± 0.17 mm in the placebo group) but was not significant (P = 0.567). 105 7-methylxanthine was shown to increase the diameter and content of collagen fibrils in the posterior sclera, along with increasing the thickness of the posterior sclera; it is postulated that it works by strengthening the sclera, although the exact mechanism remains unknown. 106 
LONG-TERM EFFICACY OF OPTICAL AND PHARMACEUTICAL APPROACHES
There is no disputing the fact that myopia can be slowed to clinically relevant levels with 1 or more optical and pharmaceutical approaches. However, there are limited long-term data. With the exception of a few trials that spanned 3 years or more in duration, 49 ,52,62,68 trials conducted using optical or pharmaceutical myopia control strategies are mostly 1 to 2 years in duration. Additionally, there is a concern that the magnitude of control may be time-dependent (ie, greater in the first year of lens wear with reduction thereafter). 68 Table 3 depicts the annual change in spherical equivalent and axial length for spectacle, contact lens, and orthokeratology trials where such data were provided. Although various methodologies were used in these trials, some reported a consistent year-to-year effect (Cheng et al 52 in 2014; +1.50 D)
whereas others showed a slight decrease in control over time (Hiraoka et al 68 in 2012) . Therefore, it is not entirely clear that the magnitude of control decreases over time. Furthermore, as eye growth declines with age, it may become increasingly difficult to detect a difference between the change in axial elongation with a treatment versus control. 68 In addition, factors such as patient dropouts from a clinical trial and compliance also possibly play a role. For example, despite the best efforts of investigators, myopic individuals who progress faster during the trial may see no benefit from participating in the trial and are much more likely to discontinue and seek other treatments. Higher dropout rates from the control/placebo group, which may remove patients who are experiencing lack of efficacy would pose a difficulty in developing unbiased estimates of treatment effect; this was noted to be a concern in other fields of medicine. 107 Additionally, the longer the trial duration, the greater the risk of noncompliance and the greater the risk that overall efficacy will seem reduced. Indeed, compliance was found to be a factor with much greater slowing of myopia found in eyes that were compliant. 61 Compliance issues are more likely to occur where there is no immediate benefit perceived with the use of intervention, for example, pharmaceutical applications such as atropine. These issues need to be considered carefully before weighing in on the long-term efficacy of myopia control strategies.
REBOUND OF MYOPIA
Classically, "rebound effect" defines a state of reappearance or reversal of the condition, symptoms, or underlying state upon abrupt cessation of treatment. Rebound effect was observed with the use of many pharmaceutical agents and was considered a result of the body's response to return to the basal state after an altered state or a withdrawal symptom to the cessation of the drug. In the context of myopia progression, rebound refers to an increased rate of progression upon discontinuation of treatment as compared with the rate of progression of a comparative control or to self-progression during treatment. 35 Progression of myopia at a faster rate after treatment compared with that during treatment, and in comparison with a control group, was observed with the use of atropine. 35, 108 At the end of 1 year of nontreatment, net myopia was less in the eye that experienced the rebound compared with the control eye, 35 but it remains unknown if the final myopia would have been similar to that of the control eye if the follow-up was longer than 1 year. When data were analyzed by FIGURE 2. Relationship between concentration of atropine and efficacy with respect to spherical equivalent (Sph Eq.) and axial length (AL). 32  48  3  33  44  3  13  7  53  50  46  58   35  45  2  34  34  9  13  27  46  37  43  52 6-month periods, although eyes that discontinued atropine treatment had greater progression in both the first and second 6-month periods, 35 significantly less progression was noted in the second 6-month period indicating that much of the rebound occurred in the months immediately after discontinuation. Although the exact mechanism of action is unknown, there is much evidence from systemic and ocular use of drugs indicating that tapering the drug dosage rather than abrupt withdrawal generally keeps the rebound at bay. Rebound upon cessation of atropine is considered to be dose dependent with little rebound with lower concentrations 108 ; however, to date there are no data on the efficiency of tapered doses in limiting rebound.
Although rebound is a phenomenon commonly observed with abrupt withdrawal of medications, there is a concern as to whether optical strategies for myopia control are also prone to rebound effect. When eyes that wore progressive addition spectacles were switched to single-vision lenses, the rate of progression was not greater than expected with single-vision spectacles, and therefore it was concluded that there was no rebound. 60 In a later study involving contralateral orthokeratology and rigid gas permeable lenses, treatments were switched between eyes after 6 months of lens wear; eyes that switched from orthokeratology to rigid gas permeable lenses exhibited a greater axial length change compared with eyes that wore rigid gas permeable lenses in the first 6 months or had a rebound effect. 38 A later study also found that discontinuation of orthokeratology in children younger than 14 years led to rapid increase in axial length. 37 Although there is a need to better understand rebound effect with myopia control strategies, such explorations are innately difficult, as they require removal of treatment in an eye that is receiving the benefit, thus posing ethical considerations. It may be more appropriate to consider continuing myopia control treatments until after the myopia has stabilized (demonstrated by no significant change in spherical equivalent refractive error and/or axial length) for several years and the period of eye growth completed. Such treatments could also incorporate tapering should the need arise to discontinue the treatment.
CONCLUSIONS
Until recently, myopia was simply corrected with singlevision spectacles or contact lenses to restore vision. Translation of research has led to the finding that progression of eye growth in myopic eyes can be slowed using several approaches including use of specially designed spectacles and contact lenses along with orthokeratology and pharmaceutical agents. Although the overall efficacy varies among the different approaches, they all have a role to play in managing the condition as the age of the individual, suitability, affordability, safety of the strategy, subjective needs of the individual, and rate of progression influence the selection of the appropriate approach. A number of important questions remain in relation to long-term efficacy and rebound effect which need to be explored further. There also exists a risk, although rare, for developing sight-threatening complications such as microbial keratitis with contact lenses and orthokeratology and for developing adverse effects related to pupil and accommodation with atropine. These need to be given due consideration in the overall risk versus benefit approach when prescribing myopia control treatment. But overall, the emerging data are promising as this new body of information indicates that there are a number of ways to significantly reduce the risk of the eye reaching higher levels of myopia.
